Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2012-02-16

FDA Approved: EXFORGE HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

A supplemental application for Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide) submitted by Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Exforge HCT (amlodipine/valsartan/hydrochlorothiazide)

Snippet

SUPPL AP for EXFORGE HCT (AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE)